Wyeth Premarin Memory Data Are Mixed On Dementia Risk; 91% Of Rxs For Vasomotor Relief
This article was originally published in The Pink Sheet Daily
Executive Summary
Negative safety findings from the Women's Health Initiative have swung Premarin scripts away from most indicated and off-label uses. The WHI Memory Study finds significantly increased risk of dementia when estrogen data are pooled with Prempro, but not among Premarin-only patients alone.
You may also be interested in...
WHI Premarin Results Support Short-Term Use; Breast Cancer Reduction May Be Bright Spot
Data from the estrogen-only arm of Women's Health Initiative show increased risk of stroke, no effect on heart disease, and a trend towards reduced breast cancer. NIH says the results parallel current clinical recommendations that hormone therapy be used at the lowest dose for the shortest period of time.
Premarin WHI Results May Mean Additional Label Changes, FDA Says
The findings could lead FDA to revise the class labeling for hormone therapies to reflect the absence of risk of heart disease and invasive breast cancer among estrogen-only patients.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.